Welcome to Dermbits! Watch short videos of KOLs answering your questionsSee all conditionsAcneActinic KeratosisAestheticsAlopeciaAtopic DermatitisConnective Tissue DiseasesCOVID-19Cutaneous MelanomaEczemaGeneralized Pustular Psoriasis (GPP)Hair and NailsHidradenitis SuppurativaJAK InhibitorsNB-UVBPigmentary DisordersPsoriasisPsoriatic ArthritisRosaceaSkin CancerSunscreenTopical TherapiesVitiligoWarts And MolluscumPsoriasisAre there specific patient populations who are at higher risk for adverse effects from ixekizumab?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisWhat are the considerations for using ixekizumab in patients with a history of serious infections?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisDoes patient weight impact the dosing and efficacy of ixekizumab?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisWhat strategies can be used to taper ixekizumab in patients with sustained remission?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisCan ixekizumab therapy lead to sustained remission or disease modification in patients with psoriasis?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisShould ixekizumab be used as a monotherapy, or can it be used concomitantly with other therapies?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisAre there any special considerations for transitioning patients with psoriasis from other biologic agents to ixekizumab?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisWhat factors contribute to the progression from mild to severe psoriasis?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisHow can early intervention impact the long-term course of psoriasis?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisHow can dermatologists encourage a holistic approach to psoriasis treatment, including lifestyle modifications and mental health support?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisHow does ixekizumab impact cardiovascular risk factors in patients with psoriasis?Featuring Tina Bhutani, MD, MASPsoriasisWhat are the long-term outcomes of ixekizumab therapy in terms of durability of response and maintenance of skin clearance?Featuring Tina Bhutani, MD, MASPsoriasisHow does ixekizumab influence the risk of infections in patients with psoriasis?Featuring Tina Bhutani, MD, MASPsoriasisIs there any benefit to extending the dosing interval of ixekizumab in patients with stable psoriasis?Featuring Tina Bhutani, MD, MASPsoriasisIs there any evidence to suggest ixekizumab is more effective in certain psoriasis phenotypes or patient subgroups?Featuring Tina Bhutani, MD, MASPsoriasisWhat lifestyle modifications should be recommended to patients receiving ixekizumab?Featuring Tina Bhutani, MD, MASPsoriasisWhat is the recommended monitoring for patients with psoriasis receiving ixekizumab?Featuring Tina Bhutani, MD, MASPsoriasisWhat is the role of biopsy in confirming a diagnosis of psoriasis?Featuring Tina Bhutani, MD, MASPsoriasisWhat role do patient preferences play in selecting a psoriasis treatment regimen?Featuring Tina Bhutani, MD, MASPsoriasisHow do you address patient concerns about the long-term use of biologics?Featuring Tina Bhutani, MD, MASPsoriasisWhat are the most common side effects associated with ixekizumab in long-term use?Featuring Laura Ferris, MD, PhDPsoriasisHow does ixekizumab's mechanism of action differ from that of other biologics used for psoriasis?Featuring Laura Ferris, MD, PhDPsoriasisHow does the recommended dosing regimen for ixekizumab compare to those of other biologics for psoriasis?Featuring Laura Ferris, MD, PhDPsoriasisCan ixekizumab be used in combination with topical treatments, and if so, what is the recommended approach?Featuring Laura Ferris, MD, PhDPsoriasisIs there a need for loading doses when initiating ixekizumab therapy?Featuring Laura Ferris, MD, PhDPsoriasisHow should dermatologists approach ixekizumab therapy in patients planning to conceive?Featuring Laura Ferris, MD, PhDPsoriasisWhat considerations should be made for elderly patients starting ixekizumab?Featuring Laura Ferris, MD, PhDPsoriasisWhat are the considerations for using ixekizumab in patients with comorbidities such as diabetes or cardiovascular disease?Featuring Laura Ferris, MD, PhDPsoriasisHow should dermatologists address concerns about injection-site reactions in patients starting ixekizumab?Featuring Laura Ferris, MD, PhDPsoriasisHow should psoriasis be managed in patients with a history of liver disease?Featuring Laura Ferris, MD, PhDPsoriasisWhat monitoring is essential for patients on long-term systemic psoriasis therapies?Featuring Laura Ferris, MD, PhDPsoriasisWhat strategies can be used to improve patient adherence in psoriasis treatment regimens?Featuring Laura Ferris, MD, PhDPsoriasisHow does the safety profile of ixekizumab compare to other IL-17 inhibitors?Featuring Saakshi Khattri , MDPsoriasisHow soon can patients on ixekizumab for psoriasis expect to see results?Featuring Saakshi Khattri , MDPsoriasisCan ixekizumab be safely used in patients with comorbidities like hepatitis B or tuberculosis?Featuring Saakshi Khattri , MDPsoriasisWho is the ideal patient for ixekizumab, and are there any notable exclusions?Featuring Saakshi Khattri , MDPsoriasisWhat patient education points are important to convey to patients starting ixekizumab?Featuring Saakshi Khattri , MDPsoriasisAre there any dose adjustments needed for patients with renal or hepatic impairment when using ixekizumab?Featuring Saakshi Khattri , MDPsoriasisAre there any head-to-head studies comparing ixekizumab to other biologics?Featuring Saakshi Khattri , MDPsoriasisDo patients with nail and scalp psoriasis have a greater risk of developing psoriatic arthritis?Featuring Saakshi Khattri , MDPsoriasisWhat are the most important factors to consider when selecting a first-line biologic for patients with psoriasis?Featuring Saakshi Khattri , MDPsoriasisHow do you manage patients with psoriasis with concurrent inflammatory bowel disease?Featuring Saakshi Khattri , MDPsoriasisWhat are the most common adverse reactions seen with ixekizumab?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisWhat is the dosing regimen for ixekizumab?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisWhat factors should be considered when determining optimal treatment duration for ixekizumab in patients with psoriasis?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisIs ixekizumab safe for use in pediatric populations?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisWhat is the mechanism of action of ixekizumab?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisWhen do you consider a biologic as a first-line treatment for psoriasis?Featuring Raj Chovatiya, MD, PhD, MSCILoad more videos48 of 213Previous pageNext page
